Free Trial

Finch Therapeutics Group (FNCH) Competitors

Finch Therapeutics Group logo
$12.05 0.00 (0.00%)
As of 10/24/2025

FNCH vs. HOWL, COEP, GANX, ELYM, RLMD, AADI, LITS, ABVC, INKT, and CRVO

Should you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Werewolf Therapeutics (HOWL), Coeptis Therapeutics (COEP), Gain Therapeutics (GANX), Eliem Therapeutics (ELYM), Relmada Therapeutics (RLMD), Aadi Bioscience (AADI), Lite Strategy (LITS), ABVC BioPharma (ABVC), MiNK Therapeutics (INKT), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.

Finch Therapeutics Group vs. Its Competitors

Werewolf Therapeutics (NASDAQ:HOWL) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Werewolf Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.

Werewolf Therapeutics has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Werewolf Therapeutics$1.88M43.05-$70.51M-$1.64-1.08
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.37

In the previous week, Werewolf Therapeutics had 3 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for Werewolf Therapeutics and 0 mentions for Finch Therapeutics Group. Werewolf Therapeutics' average media sentiment score of 0.87 beat Finch Therapeutics Group's score of 0.00 indicating that Werewolf Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Werewolf Therapeutics Positive
Finch Therapeutics Group Neutral

Finch Therapeutics Group's return on equity of -69.14% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Werewolf TherapeuticsN/A -111.87% -62.68%
Finch Therapeutics Group N/A -69.14%-26.92%

Werewolf Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 351.98%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than Finch Therapeutics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Werewolf Therapeutics beats Finch Therapeutics Group on 11 of the 15 factors compared between the two stocks.

Get Finch Therapeutics Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FNCH vs. The Competition

MetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$19.35M$347.58M$6.25B$10.65B
Dividend YieldN/AN/A5.71%4.82%
P/E Ratio-1.37N/A30.7530.52
Price / SalesN/A495.53585.15186.19
Price / CashN/A22.4437.0161.44
Price / Book0.853.7412.056.61
Net Income-$74.75M-$133.30M$3.33B$277.10M
7 Day Performance-0.41%2.51%1.88%2.54%
1 Month Performance-4.21%4.48%7.71%3.76%
1 Year Performance0.84%0.77%56.33%33.04%

Finch Therapeutics Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FNCH
Finch Therapeutics Group
0.8937 of 5 stars
$12.05
flat
N/A+0.4%$19.35MN/A-1.37190
HOWL
Werewolf Therapeutics
3.5224 of 5 stars
$1.58
-1.9%
$8.00
+406.6%
-42.1%$70.88M$1.88M-0.9540News Coverage
Analyst Forecast
COEP
Coeptis Therapeutics
0.7944 of 5 stars
$14.70
-2.1%
N/A+255.5%$70.85MN/A-2.532News Coverage
Analyst Forecast
Short Interest ↑
GANX
Gain Therapeutics
3.2424 of 5 stars
$1.94
-7.9%
$7.86
+306.1%
-26.1%$69.02M$50K-3.0520Positive News
Options Volume
ELYM
Eliem Therapeutics
N/A$2.26
-2.6%
N/A-57.2%$67.24MN/A-4.269Gap Up
High Trading Volume
RLMD
Relmada Therapeutics
2.8308 of 5 stars
$2.01
-10.5%
$1.00
-50.1%
-42.1%$66.55MN/A-0.9010
AADI
Aadi Bioscience
N/A$2.66
+20.4%
N/A+25.6%$65.69M$25.07M-1.1740High Trading Volume
LITS
Lite Strategy
N/A$1.84
-5.6%
N/AN/A$65.60M$65.30M-0.39100Positive News
Gap Down
ABVC
ABVC BioPharma
0.6449 of 5 stars
$2.78
-4.8%
N/A+314.5%$65.45M$391.24K-16.3530News Coverage
Positive News
Analyst Forecast
INKT
MiNK Therapeutics
2.8705 of 5 stars
$14.30
-3.8%
$37.50
+162.2%
+106.9%$64.64MN/A-4.9730Positive News
CRVO
CervoMed
3.4918 of 5 stars
$6.91
-4.3%
$19.86
+187.4%
-43.8%$63.73M$9.74M-2.644Analyst Forecast

Related Companies and Tools


This page (NASDAQ:FNCH) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners